01—Abstract
Summary
Summary of the 10-Q filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported mixed results for the first quarter of 2025.
Total revenues decreased slightly year-over-year to $3.03 billiona from $3.15 billion, primarily driven by a significant decline in U.S. EYLEA sales due to competitive pressures and the transition to EYLEA HD. However, this was partially offset by strong growth in Dupixent and a solid performance from EYLEA HD in the U.S. Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year's quarter.
This improvement was supported by an increase in collaboration revenue, particularly from Sanofi, and a favorable shift in other income (expense), net. The company also announced its first quarterly cash dividend and continued its share repurchase program, signaling a commitment to returning capital to shareholders.
02—Key points
Key Highlights
- Total revenues declined 3.7% to $3.03 billion, mainly due to a 39% drop in U.S. EYLEA sales.
- Net income rose 12% to $808.7 million, with diluted EPS increasing to $7.27 from $6.27.
- Collaboration revenue increased 27% to $1.18 billion, driven by strong performance in the Sanofi collaboration (Dupixent and Kevzara).
- U.S. EYLEA HD sales showed strong growth, up 111% to $306.8 million, though total EYLEA and EYLEA HD sales declined 16% due to the drop in EYLEA.
- Research and development expenses increased by 6.3% to $1.33 billion.
- The company declared its first quarterly cash dividend of $0.88 per share.
- Regeneron continued its share repurchase program, buying back $1.05 billion of common stock in the quarter.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 29, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $3.03B$3.15B | −3.7% |
| R&D Expenses | $1.33B$1.25B | +6.3% |
| SG&A Expenses | $633.00M$689.00M | −8.1% |
| Operating Expenses | $2.44B$2.39B | +1.8% |
| Operating Income | $591.70M$751.40M | −21.3% |
| Net Income | $808.70M$722.00M | +12.0% |
| EPS (Basic) | $7.58$6.70 | +13.1% |
| EPS (Diluted) | $7.27$6.27 | +15.9% |
| Shares Outstanding (Basic) | 106.70M107.80M | −1.0% |
| Shares Outstanding (Diluted) | 111.20M115.10M | −3.4% |
05—Questions
Frequently Asked Questions
What was the primary driver of the revenue decline?
The primary driver of the revenue decline was the significant decrease in U.S. EYLEA sales, which fell by 39% year-over-year. This was attributed to competitive pressures, loss of market share to compounded bevacizumab due to affordability constraints, and the ongoing transition of patients to EYLEA HD.
How did the company's collaboration revenues perform?
Collaboration revenues increased significantly by 27% to $1.18 billion. This growth was primarily fueled by Regeneron's share of profits from the Sanofi collaboration, particularly from Dupixent sales, which increased by 32% to $1.02 billion.
What is the company's outlook regarding EYLEA and EYLEA HD?
Regeneron anticipates continued pressure on EYLEA sales due to competition and the transition to EYLEA HD. While EYLEA HD demonstrated strong growth in the U.S., the company faces ongoing competition from other anti-VEGF products and biosimilars. Regulatory decisions for extended dosing intervals and a pre-filled syringe for EYLEA HD are pending.
What is the significance of the company declaring its first quarterly cash dividend?
The declaration of its first quarterly cash dividend of $0.88 per share in February 2025 signals Regeneron's increasing financial strength and commitment to returning capital to shareholders. This move is often viewed positively by investors as it indicates confidence in future cash flows.
06—Continue